{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T03:40:34Z","timestamp":1768448434613,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s11934-023-01174-5","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T08:01:38Z","timestamp":1688371298000},"page":"471-476","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Stereotactic Body Radiation Therapy Salvage for Lymph Node Recurrent Prostate Cancer in the Era of PSMA PET Imaging"],"prefix":"10.1007","volume":"24","author":[{"given":"Omar E.","family":"Hayek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soroush","family":"Rais-Bahrami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1592-9950","authenticated-orcid":false,"given":"Samuel J.","family":"Galgano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,3]]},"reference":[{"issue":"1","key":"1174_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.eururo.2016.07.043","volume":"71","author":"DE Spratt","year":"2017","unstructured":"Spratt DE, et al. Patterns of lymph node failure after dose-escalated radiotherapy: implications for extended pelvic lymph node coverage. Eur Urol. 2017;71(1):37\u201343.","journal-title":"Eur Urol"},{"issue":"3","key":"1174_CR2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/bju.13792","volume":"120","author":"WC Jackson","year":"2017","unstructured":"Jackson WC, et al. Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study. BJU Int. 2017;120(3):351\u20137.","journal-title":"BJU Int"},{"issue":"3","key":"1174_CR3","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2016.08.055","volume":"71","author":"WP Parker","year":"2017","unstructured":"Parker WP, et al. Identification of site-specific recurrence following primary radiation therapy for prostate cancer using C-11 choline positron emission tomography\/computed tomography: a nomogram for predicting extrapelvic disease. Eur Urol. 2017;71(3):340\u20138.","journal-title":"Eur Urol"},{"key":"1174_CR4","doi-asserted-by":"crossref","unstructured":"Imber BS, et al.\u00a0Failure patterns by PSMA PET for recurrent prostate cancer after prostatectomy and salvage radiation. Urology. 2022.","DOI":"10.1016\/j.urology.2022.08.035"},{"issue":"3","key":"1174_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41391-019-0163-0","volume":"22","author":"S Raveenthiran","year":"2019","unstructured":"Raveenthiran S, et al. The use of (68)Ga-PET\/CT PSMA to determine patterns of disease for biochemically recurrent prostate cancer following primary radiotherapy. Prostate Cancer Prostatic Dis. 2019;22(3):385\u201390.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"1174_CR6","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.ijrobp.2021.12.164","volume":"112","author":"S Raman","year":"2022","unstructured":"Raman S, et al. Patterns of prostate cancer recurrence after brachytherapy determined by prostate-specific membrane antigen-positron emission tomography and computed tomography imaging. Int J Radiat Oncol Biol Phys. 2022;112(5):1126\u201334.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1174_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00345-020-03344-3","volume":"39","author":"E Mena","year":"2021","unstructured":"Mena E, et al. Novel PET imaging methods for prostate cancer. World J Urol. 2021;39(3):687\u201399.","journal-title":"World J Urol"},{"key":"1174_CR8","doi-asserted-by":"crossref","unstructured":"Galgano, SJ, et al.\u00a0Defining oligometastatic disease in the new era of PSMA-PET imaging for primary staging of prostate cancer. Cancers (Basel). 2022;14(14).","DOI":"10.3390\/cancers14143302"},{"key":"1174_CR9","doi-asserted-by":"crossref","unstructured":"Schwartz LH, et al.\u00a0Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer. 2009;45(2):261\u20137.","DOI":"10.1016\/j.ejca.2008.10.028"},{"issue":"10","key":"1174_CR10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.4329\/wjr.v9.i10.389","volume":"9","author":"JG Zarzour","year":"2017","unstructured":"Zarzour JG, et al. Lymph node imaging in initial staging of prostate cancer: an overview and update. World J Radiol. 2017;9(10):389\u201399.","journal-title":"World J Radiol"},{"key":"1174_CR11","unstructured":"National Comprehensive Cancer Network. Prostate Cancer (Version 3.2022). April 22, 2022]; Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"issue":"5","key":"1174_CR12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1607529","volume":"376","author":"WU Shipley","year":"2017","unstructured":"Shipley WU, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med. 2017;376(5):417\u201328.","journal-title":"N Engl J Med"},{"issue":"12","key":"1174_CR13","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/S1470-2045(19)30486-3","volume":"20","author":"C Carrie","year":"2019","unstructured":"Carrie C, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 2019;20(12):1740\u20139.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1174_CR14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/RLU.0000000000003558","volume":"46","author":"C Onal","year":"2021","unstructured":"Onal C, et al. Oligometastatic bone disease in castration-sensitive prostate cancer patients treated with stereotactic body radiotherapy using 68Ga-PSMA PET\/CT: TROD 09\u2013004 study. Clin Nucl Med. 2021;46(6):465\u201370.","journal-title":"Clin Nucl Med"},{"issue":"4","key":"1174_CR15","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.eururo.2018.06.004","volume":"74","author":"S Siva","year":"2018","unstructured":"Siva S, et al. Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur Urol. 2018;74(4):455\u201362.","journal-title":"Eur Urol"},{"issue":"5\u20136","key":"1174_CR16","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.canrad.2014.07.153","volume":"18","author":"G Cr\u00e9hange","year":"2014","unstructured":"Cr\u00e9hange G, et al. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how? Cancer Radiother. 2014;18(5\u20136):524\u201334.","journal-title":"Cancer Radiother"},{"issue":"4","key":"1174_CR17","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1016\/j.clgc.2014.12.014","volume":"13","author":"E Ponti","year":"2015","unstructured":"Ponti E, et al. Salvage stereotactic body radiotherapy for patients with prostate cancer with isolated lymph node metastasis: a single-center experience. Clin Genitourin Cancer. 2015;13(4):e279\u201384.","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"1174_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13014-017-0833-9","volume":"12","author":"T Leroy","year":"2017","unstructured":"Leroy T, et al. Salvage robotic SBRT for local prostate cancer recurrence after radiotherapy: preliminary results of the Oscar Lambret Center. Radiat Oncol. 2017;12(1):95.","journal-title":"Radiat Oncol"},{"issue":"2","key":"1174_CR19","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.radonc.2018.06.027","volume":"129","author":"H Lieng","year":"2018","unstructured":"Lieng H, et al. Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiother Oncol. 2018;129(2):377\u201386.","journal-title":"Radiother Oncol"},{"issue":"1","key":"1174_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s13014-019-1383-0","volume":"14","author":"C Panje","year":"2019","unstructured":"Panje C, et al. Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice. Radiat Oncol. 2019;14(1):177.","journal-title":"Radiat Oncol"},{"issue":"8","key":"1174_CR21","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1007\/s00066-021-01871-5","volume":"198","author":"S Cozzi","year":"2022","unstructured":"Cozzi S, et al. Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer: an investigation of 117 pelvic lymph nodes. Strahlenther Onkol. 2022;198(8):700\u20139.","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"1174_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12894-019-0515-z","volume":"19","author":"C Oehler","year":"2019","unstructured":"Oehler C, et al. Predictive factors for response to salvage stereotactic body radiotherapy in oligorecurrent prostate cancer limited to lymph nodes: a single institution experience. BMC Urol. 2019;19(1):84.","journal-title":"BMC Urol"},{"key":"1174_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.616494","volume":"10","author":"P Burkon","year":"2020","unstructured":"Burkon P, et al. Stereotactic body radiotherapy for lymph node oligometastases: real-world evidence from 90 consecutive patients. Front Oncol. 2020;10: 616494.","journal-title":"Front Oncol"},{"issue":"2","key":"1174_CR24","doi-asserted-by":"publisher","first-page":"114","DOI":"10.14735\/amko2020114","volume":"33","author":"P Burko\u0148","year":"2020","unstructured":"Burko\u0148 P, et al. Stereotactic body radiotherapy of lymph node oligometastases. Klin Onkol. 2020;33(2):114\u201322.","journal-title":"Klin Onkol"},{"issue":"1079","key":"1174_CR25","doi-asserted-by":"publisher","first-page":"20170422","DOI":"10.1259\/bjr.20170422","volume":"90","author":"C Franzese","year":"2017","unstructured":"Franzese C, et al. Stereotactic\/hypofractionated body radiation therapy as an effective treatment for lymph node metastases from colorectal cancer: an institutional retrospective analysis. Br J Radiol. 2017;90(1079):20170422.","journal-title":"Br J Radiol"},{"issue":"9","key":"1174_CR26","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1016\/j.clon.2016.04.040","volume":"28","author":"P Ost","year":"2016","unstructured":"\u2022 Ost P, et al. Pattern of progression after stereotactic body radiotherapy for oligometastatic prostate cancer nodal recurrences. Clin Oncol (R Coll Radiol). 2016;28(9):e115\u201320.\u00a0Most comprehensive report of pattern of recurrence following SBRT for oligorecurrent nodal prostate cancer.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"7","key":"1174_CR27","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00066-021-01778-1","volume":"197","author":"M Pinkawa","year":"2021","unstructured":"Pinkawa M, et al. Radiotherapy in nodal oligorecurrent prostate cancer. Strahlenther Onkol. 2021;197(7):575\u201380.","journal-title":"Strahlenther Onkol"},{"issue":"8","key":"1174_CR28","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","volume":"44","author":"A Afshar-Oromieh","year":"2017","unstructured":"Afshar-Oromieh A, et al. Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017;44(8):1258\u201368.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"1174_CR29","doi-asserted-by":"publisher","first-page":"786","DOI":"10.2967\/jnumed.118.219501","volume":"60","author":"TA Hope","year":"2019","unstructured":"Hope TA, et al. Metaanalysis of (68)Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology. J Nucl Med. 2019;60(6):786\u201393.","journal-title":"J Nucl Med"},{"issue":"10","key":"1174_CR30","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1097\/COC.0000000000000419","volume":"41","author":"S Tran","year":"2018","unstructured":"Tran S, et al. Oligorecurrent nodal prostate cancer: long-term results of an elective nodal irradiation approach. Am J Clin Oncol. 2018;41(10):960\u20132.","journal-title":"Am J Clin Oncol"},{"key":"1174_CR31","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.radonc.2022.10.005","volume":"176","author":"T Zilli","year":"2022","unstructured":"Zilli T, et al. Recommendations for radiation therapy in oligometastatic prostate cancer: an ESTRO-ACROP Delphi consensus. Radiother Oncol. 2022;176:199\u2013207.","journal-title":"Radiother Oncol"},{"issue":"1","key":"1174_CR32","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1186\/s12885-020-06911-4","volume":"20","author":"A De Bruycker","year":"2020","unstructured":"\u2022 De Bruycker A, et al. PEACE V - Salvage treatment of oligorecurrent nodal prostate cancer metastases (STORM): a study protocol for a randomized controlled phase II trial. BMC Cancer. 2020;20(1):406.\u00a0First prospective evaluation evaluating metastasis-directed therapy (MDT) versus MDT in conjunction with whole pelvic radiotherapy in patients with oligometastatic recurrent prostate cancer detected on PSMA or choline PET.","journal-title":"BMC Cancer"},{"issue":"2","key":"1174_CR33","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ijrobp.2013.09.053","volume":"88","author":"J Verma","year":"2014","unstructured":"Verma J, et al. Dosimetric predictors of duodenal toxicity after intensity modulated radiation therapy for treatment of the para-aortic nodes in gynecologic cancer. Int J Radiat Oncol Biol Phys. 2014;88(2):357\u201362.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"1174_CR34","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"\u2022 Phillips R, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6(5):650\u20139.\u00a0Treatment with SABR for oligometastatic prostate cancer improved outcomes and was enhanced by total consolidation of disease identified by PSMA-targeted positron emission tomography.","journal-title":"JAMA Oncol"},{"key":"1174_CR35","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.urology.2019.05.022","volume":"132","author":"SJ Galgano","year":"2019","unstructured":"Galgano SJ, et al. [(18)F]Fluciclovine-PET guided salvage lymph node dissection following radical prostatectomy. Urology. 2019;132:28\u201332.","journal-title":"Urology"},{"issue":"12","key":"1174_CR36","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11934-020-01011-z","volume":"21","author":"H McCloskey","year":"2020","unstructured":"McCloskey H, et al. Salvage pelvic lymph node dissection and current state of imaging for recurrent prostate cancer: does a standard exist? Curr Urol Rep. 2020;21(12):62.","journal-title":"Curr Urol Rep"},{"issue":"1","key":"1174_CR37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13014-021-01776-8","volume":"16","author":"P Rogowski","year":"2021","unstructured":"Rogowski P, et al. Radiotherapy of oligometastatic prostate cancer: a systematic review. Radiat Oncol. 2021;16(1):50.","journal-title":"Radiat Oncol"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-023-01174-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11934-023-01174-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-023-01174-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T05:05:20Z","timestamp":1696223120000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11934-023-01174-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,3]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1174"],"URL":"https:\/\/doi.org\/10.1007\/s11934-023-01174-5","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,3]]},"assertion":[{"value":"19 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"None relevant to the manuscript content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}